FDA Accepts for Review Spectrum Pharmaceuticals' ZEVALIN Submission for the Removal of the Bioscan

FDA Accepts for Review Spectrum Pharmaceuticals' ZEVALIN Submission for the Removal of the Bioscan Spectrum Pharmaceuticals SPPI announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement containing data providing for the removal of the Indium-111 ZEVALIN pre-treatment imaging evaluation, more commonly referred to as the “bioscan” requirement. A decision is expected by November 20, 2011.